PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 44 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $41,430,000 | +105859.1% | 1,500,000 | -11.8% | 2.32% | -9.9% |
| Q1 2023 | $39,100 | -98.5% | 1,700,000 | +344.9% | 2.58% | +1255.3% |
| Q2 2018 | $2,568,000 | -21.8% | 382,139 | 0.0% | 0.19% | -22.4% |
| Q1 2018 | $3,283,000 | -60.5% | 382,139 | -4.5% | 0.24% | -71.9% |
| Q4 2017 | $8,320,000 | -5.8% | 400,000 | -20.0% | 0.87% | -44.2% |
| Q3 2017 | $8,835,000 | +56.2% | 500,000 | 0.0% | 1.56% | +66.5% |
| Q2 2017 | $5,655,000 | -35.4% | 500,000 | -26.9% | 0.94% | -26.3% |
| Q1 2017 | $8,757,000 | -44.7% | 683,600 | -5.1% | 1.27% | -40.4% |
| Q4 2016 | $15,833,000 | -6.3% | 720,000 | -10.0% | 2.13% | +14.5% |
| Q3 2016 | $16,904,000 | – | 800,000 | – | 1.86% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $26,721 | 7.77% |
| Bain Capital Life Sciences Investors, LLC | 2,364,410 | $25,796 | 2.88% |
| Sio Capital Management, LLC | 434,635 | $4,741,868 | 1.75% |
| Tri Locum Partners LP | 199,500 | $2,177,000 | 0.88% |
| Kynam Capital Management, LP | 520,922 | $5,683,259 | 0.87% |
| RTW INVESTMENTS, LP | 3,591,986 | $39,188,567 | 0.80% |
| Madison Avenue Partners, LP | 406,593 | $4,435,930 | 0.79% |
| Deep Track Capital, LP | 871,493 | $9,507,989 | 0.40% |
| Soleus Capital Management, L.P. | 236,000 | $2,574,760 | 0.37% |
| BRAIDWELL LP | 927,800 | $10,122,298 | 0.34% |